Kitab B, Tsukiyama-Kohara K
Int J Mol Sci. 2023; 24(3).
PMID: 36768940
PMC: 9916403.
DOI: 10.3390/ijms24032619.
Yin X, Jiang K, Zhou Z, Yu H, Yan D, He X
Oxid Med Cell Longev. 2023; 2023:3878796.
PMID: 36713030
PMC: 9883104.
DOI: 10.1155/2023/3878796.
Islam M, Barshetty M, Srinivasan S, Dudekula D, Rallabandi V, Mohammed S
Biomolecules. 2022; 12(9).
PMID: 36139117
PMC: 9496582.
DOI: 10.3390/biom12091279.
Qiu H, Huang J, Xiang C, Li R, Zuo E, Zhang Y
Technol Cancer Res Treat. 2020; 19:1533033820980112.
PMID: 33302814
PMC: 7734488.
DOI: 10.1177/1533033820980112.
Zhou Y, Yang L, Zhang X, Chen R, Chen X, Tang W
Biomed Res Int. 2019; 2019:6581576.
PMID: 31119182
PMC: 6500689.
DOI: 10.1155/2019/6581576.
Differential Gene Expression in Erlotinib-Treated Fibroblasts.
Wickersham K, Hodges T, Edelman M, Song Y, Nan M, Dorsey S
Nurs Res. 2018; 68(2):110-126.
PMID: 30540703
PMC: 7580303.
DOI: 10.1097/NNR.0000000000000330.
Ribonucleotide Reductase Inhibitor 3-AP Induces Oncogenic Virus Infected Cell Death and Represses Tumor Growth.
Dai L, Chen J, Cao Y, Del Valle L, Qin Z
J Cancer. 2018; 9(23):4503-4509.
PMID: 30519356
PMC: 6277659.
DOI: 10.7150/jca.27437.
Downregulation of ribonucleotide reductase subunits M2 induces apoptosis and G1 arrest of cervical cancer cells.
Wang N, Li Y, Zhou J
Oncol Lett. 2018; 15(3):3719-3725.
PMID: 29556274
PMC: 5844123.
DOI: 10.3892/ol.2018.7806.
Targeting Nucleotide Biosynthesis: A Strategy for Improving the Oncolytic Potential of DNA Viruses.
Irwin C, Hitt M, Evans D
Front Oncol. 2017; 7:229.
PMID: 29018771
PMC: 5622948.
DOI: 10.3389/fonc.2017.00229.
Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma.
Dai L, Lin Z, Qiao J, Chen Y, Flemington E, Qin Z
Oncogene. 2017; 36(35):5068-5074.
PMID: 28459467
PMC: 5578886.
DOI: 10.1038/onc.2017.122.
Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.
Goss K, Gordon D
Oncotarget. 2016; 7(39):63003-63019.
PMID: 27557498
PMC: 5325343.
DOI: 10.18632/oncotarget.11416.
Repositioning of a cyclin-dependent kinase inhibitor GW8510 as a ribonucleotide reductase M2 inhibitor to treat human colorectal cancer.
Hsieh Y, Chou C, Lo H, Yang P
Cell Death Discov. 2016; 2:16027.
PMID: 27551518
PMC: 4979501.
DOI: 10.1038/cddiscovery.2016.27.
A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study.
Kirschbaum M, Frankel P, Synold T, Xie Z, Yen Y, Popplewell L
Leuk Lymphoma. 2016; 57(10):2307-14.
PMID: 26895565
PMC: 4969190.
DOI: 10.3109/10428194.2016.1146947.
Whole genome RNAi screens reveal a critical role of REV3 in coping with replication stress.
Kotov I, Siebring-van Olst E, Knobel P, van der Meulen-Muileman I, Felley-Bosco E, van Beusechem V
Mol Oncol. 2014; 8(8):1747-59.
PMID: 25113059
PMC: 5528584.
DOI: 10.1016/j.molonc.2014.07.008.
Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies.
Aye Y, Li M, Long M, Weiss R
Oncogene. 2014; 34(16):2011-21.
PMID: 24909171
DOI: 10.1038/onc.2014.155.
Ribonucleotide reductase metallocofactor: assembly, maintenance and inhibition.
Zhang C, Liu G, Huang M
Front Biol (Beijing). 2014; 9(2):104-113.
PMID: 24899886
PMC: 4041730.
DOI: 10.1007/s11515-014-1302-6.
The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients.
Su Y, Wu T, Ko J, Tsai H, Tee Y, Chien M
PLoS One. 2014; 9(3):e91644.
PMID: 24637958
PMC: 3956764.
DOI: 10.1371/journal.pone.0091644.
Increased expression of RRM2 by human papillomavirus E7 oncoprotein promotes angiogenesis in cervical cancer.
Wang N, Zhan T, Ke T, Huang X, Ke D, Wang Q
Br J Cancer. 2014; 110(4):1034-44.
PMID: 24423925
PMC: 3929894.
DOI: 10.1038/bjc.2013.817.
A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.
Zhou B, Su L, Hu S, Hu W, Yip M, Wu J
Cancer Res. 2013; 73(21):6484-93.
PMID: 24072748
PMC: 3823501.
DOI: 10.1158/0008-5472.CAN-13-1094.
Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.
Klisovic R, Blum W, Liu Z, Xie Z, Kefauver C, Huynh L
Leuk Lymphoma. 2013; 55(6):1332-6.
PMID: 24015841
PMC: 4298748.
DOI: 10.3109/10428194.2013.838764.